Chemed (NYSE:CHE) -16.2% premarket after the U.S. sues the hospice chain and several of its...

Chemed (NYSE:CHE) -16.2% premarket after the U.S. sues the hospice chain and several of its subsidiaries, alleging they submitted false Medicare billings for services that misspent "tens of millions of taxpayer dollars." In one instance cited by the government, CHE subsidiary Vitas Hospice billed a patient for care he didn't need and at a time when he was actually playing bingo.